723281-72-9 Usage
Description
6-Bromo-4-Chloro-3-Nitroquinoline is a complex chemical compound that features a quinoline structure with bromine, chlorine, and nitrogen atoms, as well as an oxygen atom. It is characterized by a distinct color and crystalline form. Due to its specific atomic arrangement, it is typically synthesized under controlled laboratory conditions. While there is limited information on its potential applications, toxicity, or safety, it is known that similar quinoline-based compounds are utilized in the production of dyes, pharmaceuticals, and other scientific applications. It is essential to handle this compound with care in a professional and controlled environment.
Uses
Used in Chemical Synthesis:
6-Bromo-4-Chloro-3-Nitroquinoline is used as an intermediate compound in the synthesis of various chemical products. Its unique structure allows for further reactions and modifications, making it a valuable component in the creation of new molecules with potential applications in different industries.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 6-Bromo-4-Chloro-3-Nitroquinoline is used as a building block for the development of new drugs. Its quinoline structure is a common feature in many medicinal compounds, and its specific functional groups can be exploited to create novel therapeutic agents with potential applications in treating various diseases.
Used in Dye Production:
6-Bromo-4-Chloro-3-Nitroquinoline is used as a precursor in the production of dyes. Its distinct color properties make it a suitable candidate for the synthesis of dyes used in various applications, such as textiles, plastics, and printing inks.
Used in Scientific Research:
6-Bromo-4-Chloro-3-Nitroquinoline is used as a research compound in various scientific studies. Its unique structure and properties make it an interesting subject for investigation, potentially leading to new discoveries and applications in the fields of chemistry, biology, and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 723281-72-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,2,3,2,8 and 1 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 723281-72:
(8*7)+(7*2)+(6*3)+(5*2)+(4*8)+(3*1)+(2*7)+(1*2)=149
149 % 10 = 9
So 723281-72-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H4BrClN2O2/c10-5-1-2-7-6(3-5)9(11)8(4-12-7)13(14)15/h1-4H
723281-72-9Relevant articles and documents
Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitors
Bahekar, Rajesh,Dave, Bhushan,Soman, Shubhangi,Patel, Dipam,Chopade, Rajendra,Funde, Radhika,Kumar, Jeevan,Sachchidanand,Giri, Poonam,Chatterjee, Abhijit,Mahapatra, Jogeswar,Vyas, Purvi,Ghoshdastidar, Krishnarup,Bandyopadhyay, Debdutta,Desai, Ranjit C.
, p. 1313 - 1319 (2019)
PI3Kδ is implicated in various inflammatory and autoimmune diseases. For the effective treatment of chronic immunological disorders such as rheumatoid arthritis, it is essential to develop isoform selective PI3Kδ inhibitors. Structure guided optimization of an imidazo-quinolinones based pan-PI3K/m-TOR inhibitor (Dactolisib) led to the discovery of a potent and orally bioavailable PI3Kδ isoform selective inhibitor (10h), with an improved efficacy in the animal models.
QUINOLINO-PYRROLIDIN-2-ONE DERIVATIVE AND APPLICATION THEREOF
-
Paragraph 0072-0074, (2021/07/08)
Disclosed are a series of quinolino-pyrrolidin-2-one compounds, and application thereof in preparation of drugs for ATM inhibitor-related diseases. The present disclosure specifically relates to a derivative compound represented by formula (I), tautomers thereof or pharmaceutically acceptable compositions thereof.
Discovery of 1,8-disubstituted-[1,2,3]triazolo[4,5-c]quinoline derivatives as a new class of Hippo signaling pathway inhibitors
Chen, Pei,Li, L.,Lin, Guifeng,Qiao, Jingxin,Xia, A.,Xiang, Z.,Yang, Shengyong,Zhang, Guo
, (2019/08/12)
Inhibitors of the Hippo signaling pathway have been demonstrated to have a potential clinical application in cases such as tissue repair and organ regeneration. However, there is a lack of potent Hippo pathway inhibitors at present. Herein we report the discovery of a series of 1,8-disubstituted-[1,2,3]triazolo[4,5-c]quinoline derivatives as a new class of Hippo pathway inhibitors by utilizing a cell line-based screening model (A549-CTGF). Structure-activity relationship (SAR) of these compounds was also discussed. The most potent compound in the A549-CTGF cell assay, 11g, was then evaluated by real-time PCR and immunofluorescence assays. Overall, this study provides a starting point for later drug discovery targeting the Hippo signaling pathway.
